BILIX
LIVE

Serial Number

79302549

Owner

Bilix Co., Ltd.

Attorney

James R Menker

Filing Date

Nov 11, 2020

Add to watchlist:

No watchlists yet
View on USPTO

BILIX Trademark

Serial Number: 79302549 • Registration: 6835721

BILIX is a trademark filed by Bilix Co., Ltd. on November 11, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Bilix Co., Ltd. (2 trademarks)

12th Fl., 364, Gangnam-daero, Gangnam-gu

Entity Type: 03

Trademark Details

Filing Date

November 11, 2020

Registration Date

September 6, 2022

Published for Opposition

June 21, 2022

Goods & Services

Pharmaceutical preparations for neurological disease; pharmaceutical preparations for inflammatory diseases; pharmaceutical preparations for ocular and intraocular surgery; pharmaceutical preparations for rare autoimmune diseases in the nature of autoimmune lymphoproliferative syndrome, lupus, and multiple sclerosis; pharmaceutical products for the treatment of rare autoimmune diseases and disorders; pharmaceutical products for the prevention and treatment of rare genetic diseases affecting red blood cells; medicated ointments for treating dermatological conditions; antibiotic ointments; mentholated ointment for medical use; anti-inflammatory ointments; chemical reagents for purposes of medical diagnosis; diagnostic preparations for diagnosing inflammatory diseases; diagnostic radiopharmaceutical preparations; pharmaceutical and biological preparations for use in diagnosis, namely, for use as ultrasound and x-ray contrast reagents; antibiotics; anti-inflammatory preparations; anti-cancer preparations; biological preparations for the treatment of cancer; cardiovascular pharmaceutical preparations; dermatological pharmaceutical products; diagnostic preparations for medical or veterinary purposes; genetic identity tests comprised of reagents for medical purposes; human vaccine preparations; medicines for dental purposes; medicines for intestinal disorders; ophthalmic preparations; pharmaceutical agents affecting digestive organs; pharmaceutical agents affecting metabolism; pharmaceutical agents affecting peripheral nervous system; pharmaceutical agents affecting sensory organs; pharmaceutical preparations acting on the central nervous system; pharmaceutical agents for epidermis; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for peripheral nervous system; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of musculo-skeletal disorders; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for treating skin disorders; pharmaceutical products for the treatment of cancer; pharmaceutical products for the treatment of infectious diseases; pharmaceutical products for the treatment of viral diseases; pharmaceutical products for treating respiratory diseases; pharmaceuticals for the treatment of erectile dysfunction; preparations for the treatment of asthma; tumor suppressing agents; vaccines; immunoassay reagents for medical use

Pharmaceutical research services; drug discovery services; medical research; pharmaceutical product evaluation; scientific investigations for medical purposes; scientific research for medical purposes in the area of cancerous diseases; development of pharmaceutical preparations and medicines; consulting on the testing, inspection and research of medical products for quality control purposes; providing information on the testing, inspection and research of medical products for quality control purposes; industrial research in the fields of medicine, health and pharmacology; engineering services in the medical technology field

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Jan 3, 2023 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Dec 9, 2022 FICS
FINAL DISPOSITION PROCESSED
Dec 9, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 6, 2022 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 6, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Sep 6, 2022 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jul 11, 2022 OPNX
NOTIFICATION PROCESSED BY IB
Jul 5, 2022 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 22, 2022 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jun 22, 2022 OPNR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 21, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jun 21, 2022 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 8, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jun 8, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 1, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 13, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Apr 28, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Apr 28, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Apr 28, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Apr 28, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 31, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 31, 2022 CRFA
ASSIGNED TO LIE
Mar 31, 2022 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 29, 2022 TROA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 29, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 29, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 29, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 29, 2021 GNRN
NON-FINAL ACTION E-MAILED
Oct 29, 2021 GNRT
NON-FINAL ACTION WRITTEN
Oct 29, 2021 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 30, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 30, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 30, 2021 TROA
REFUSAL PROCESSED BY IB
May 17, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 26, 2021 RFCS
REFUSAL PROCESSED BY MPU
Apr 26, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 23, 2021 RFCR
NON-FINAL ACTION WRITTEN
Apr 22, 2021 CNRT
ASSIGNED TO EXAMINER
Apr 21, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 26, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 22, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 21, 2021 REPR